Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Financial Officer | March 04, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date March 04, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 531,553 |
Ending reported balance
After 2024-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-04 · Grant · Acquired 147,790 · Balance 547,009 Row 2 · 2024-03-05 · Sale · Disposed 15,456 · Balance 531,553 F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SomaLogic, Inc.
Report date January 05, 2024 · Filed January 09, 2024
Section 16 reporting ended · disclosed 2024-01-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-05 · Disposition to issuer · Disposed 185,400 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and
F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),
F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2024 Filed Mar 7, 2024 00:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,456 | $3.44 | $53,168.64 |
DisclosureSEC source: 0001062993-24-005759 · form4.xml · nonDerivative · entry 2 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,553 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 147,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005759 · form4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,009 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:48 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (right to buy) · Derivative | 185,400 | Not disclosed Strike: $2.74 | Not disclosed |
DisclosureSEC source: 0001209191-24-001326 · doc4.xml · derivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F2 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3 · price: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4 · price: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1 · derivative.exercise_date: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 134,961 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001062993-23-013930 · form4.xml · derivative · entry 4 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,868 Underlying: Common Stock · 134,961 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 64,961 | $8.14 | $528,782.54 |
DisclosureSEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 3 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.00 to $8.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 70,000 | $8.14 | $569,800.00 |
DisclosureSEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 2 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,180 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.00 to $8.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 134,961 | $7.30 | $985,215.30 |
DisclosureSEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 534,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,328 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001062993-23-013872 · form4.xml · derivative · entry 4 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,829 Underlying: Common Stock · 14,328 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,328 | $8.53 | $122,217.84 |
DisclosureSEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 3 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,328 | $7.30 | $104,594.40 |
DisclosureSEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 2 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 55,672 | $8.53 | $474,882.16 |
DisclosureSEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 08, 2023 Filed Jun 14, 2023 16:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 185,400 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-23-037071 · doc4.xml · derivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,400 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/4 of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vest monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:23 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 38,000 | $7.16 | $272,080.00 |
DisclosureSEC source: 0001062993-23-013030 · form4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,891 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 177,377 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006326 · form4.xml · derivative · entry 2 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,377 Underlying: Common Stock · 177,377 shares Expires 2033-03-06 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 118,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006326 · form4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,891 Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 597,157 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-22-034343 · doc4.xml · derivative · entry 2 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,157 Underlying: Common Stock · 597,157 shares Expires 2032-06-01 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 374,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034343 · doc4.xml · nonDerivative · entry 1 PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,688 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.